Guggenheim Capital LLC acquired a new stake in shares of Iqvia Holdings Inc (NYSE:IQV) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 561,626 shares of the medical research company’s stock, valued at approximately $54,983,000. Guggenheim Capital LLC owned about 0.27% of Iqvia as of its most recent filing with the SEC.
A number of other hedge funds have also recently made changes to their positions in the stock. QS Investors LLC purchased a new stake in Iqvia during the 4th quarter valued at about $610,000. Deutsche Bank AG purchased a new stake in shares of Iqvia during the 4th quarter valued at about $51,027,000. Virtue Capital Management LLC purchased a new stake in shares of Iqvia during the 4th quarter valued at about $358,000. Franklin Resources Inc. purchased a new stake in shares of Iqvia during the 4th quarter valued at about $34,309,000. Finally, Adi Capital Management LLC purchased a new stake in shares of Iqvia during the 4th quarter valued at about $7,427,000. 92.34% of the stock is currently owned by institutional investors.
In other Iqvia news, insider James H. Erlinger III sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Robert Parks sold 896 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $105.73, for a total transaction of $94,734.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,712 shares of company stock worth $2,176,034. 6.00% of the stock is owned by company insiders.
IQV has been the topic of a number of recent analyst reports. TheStreet raised shares of Iqvia from a “c+” rating to a “b” rating in a report on Wednesday, December 13th. Mitsubishi UFJ Financial Group initiated coverage on shares of Iqvia in a report on Friday, December 15th. They set a “neutral” rating and a $112.00 price target on the stock. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a report on Thursday, January 18th. Evercore ISI initiated coverage on shares of Iqvia in a report on Thursday, January 18th. They set an “outperform” rating and a $112.00 price target on the stock. Finally, SunTrust Banks reaffirmed a “hold” rating and set a $110.00 price target on shares of Iqvia in a report on Monday, January 22nd. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Iqvia has an average rating of “Buy” and an average target price of $110.02.
IQV opened at $94.85 on Friday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $20,166.79, a P/E ratio of 21.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.63. Iqvia Holdings Inc has a 12-month low of $78.09 and a 12-month high of $110.67.
Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.34 by ($0.02). The business had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.09 EPS. equities research analysts predict that Iqvia Holdings Inc will post 5.02 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/guggenheim-capital-llc-acquires-shares-of-561626-iqvia-holdings-inc-iqv.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.